Synopsis: Sai Parenterals Ltd shares jump 15% after its Australian subsidiary Noumed secures AUD 202 million (~1,300 crore) OTC supply contract renewal with a leading pharmacy network. The long-term deal, spanning up to 10 years, boosts revenue visibility and strengthens the company’s global pharmaceutical footprint.
The shares of the Small-Cap company, specializing in the research, development, and manufacturing of critical sterile injectables, oral solid dosages, and various other drug formulations, are in focus after announcing that its Australian subsidiary, Noumed Pharmaceuticals Pty Ltd, has successfully renewed its long-term exclusive OTC Medicines Supply Agreement.
With a market capitalisation of Rs. 2,809.58 crores in the day’s trade, the shares of Sai Parenterals Ltd rose upto 15 percent, making a high of Rs. 705.00 per share compared to its previous closing price of Rs. 611.40 per share
What Happened
Sai Parenterals Limited has announced that its Australian subsidiary, Noumed Pharmaceuticals Pty Ltd, has renewed its exclusive OTC medicines supply agreement with one of Australia’s leading pharmacy networks. Effective 1 July 2026, the renewed contract is valued at AUD 202 million (approximately Rs. 1,300 crore) over a 7.5-year term, with an option to extend for a further three years by mutual consent.
Under the renewed mandate, Noumed will continue to manage the entire value chain, including manufacturing, sourcing, TGA regulatory compliance, warehousing, quality assurance, and nationwide distribution across Australia.
The expanded agreement also includes a structured growth roadmap, targeting the addition of 12 new OTC products annually. This is expected to steadily enhance the portfolio and contract value over time, while providing Sai Parenterals with long-term revenue visibility and strengthening its international presence.
Strategic Benefits
The renewed agreement delivers strong strategic benefits, including predictable, long-term recurring revenue over 7.5 years (extendable beyond a decade), as well as a stronger position for Noumed Pharmaceuticals in the Australian OTC market. It also enhances Sai Parenterals’ international presence, improves manufacturing scale and operational efficiency, and supports the continued launch of new OTC products in partnership with leading Australian pharmacy chains.
For Sai Parenterals, the deal further strengthens global credibility in regulated pharmaceutical markets while improving utilization of its infrastructure and ensuring more stable earnings visibility. It also deepens long-standing relationships with major pharmacy retail groups and creates a solid platform for future international expansion.
Management Commentry
- Mr. Anil Kumar Karusala, Managing Director of Sai Parenterals Limited, said the renewal of the exclusive agreement reflects continued confidence from Australia’s leading pharmacy groups in Noumed Pharmaceuticals and provides a strong platform for expansion into other highly regulated markets, while also ensuring sustainable, predictable revenues, supporting future product launches, and creating long-term value for Sai Parenterals and its stakeholders, with the company committed to building further on this milestone.
- Mr. Mark Thulborne, CEO of Noumed Pharmaceuticals Pty Ltd, said that the long tenure of the renewed agreement reflects the company’s ability to build lasting customer relationships, ensure predictable revenues, and maintain strong trust through consistent delivery of quality products. He noted that the partnership has grown significantly over recent years and that the extended renewal further strengthens Noumed’s position in one of the world’s most highly regulated pharmaceutical markets as a reliable end-to-end value chain partner.
Financials & Others
The company’s revenue rose by 106 percent from Rs. 96 crores in December 2025 to Rs. 198 crores in March 2026. Meanwhile, Net loss from Rs. 7 crores turned to a profit of Rs. 13 crores in the same period.
The company currently reflects a low return profile, with ROCE at 5.97% and ROE at 4.88%, indicating modest efficiency in capital and equity utilization. However, the debt-to-equity ratio remains at a moderate 0.68, suggesting manageable leverage. On the operational side, debtor days have improved significantly from 253 to 173 days, indicating better working capital management and improved collections.
Sai Parenterals Limited, which was established in 2001, is a global IP-led pharmaceutical formulations company with operations in India and Australia. It operates manufacturing facilities in India focused on injectables and oral dosage forms, along with an upcoming oral dosage facility in Australia.
Backed by strong in-house R&D capabilities, the company has a proven track record of delivering high-quality products across diversified therapeutic segments. It serves as a trusted partner to customers across India, as well as regulated and semi-regulated international markets.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
